Clinical Trials Arena September 5, 2024
Moderna is currently running a Phase I/II trial of the mRNA mpox vaccine mRNA-1769 in healthy participants.
Moderna has announced its mRNA vaccine in development for mpox is more effective than Bavarian Nordics Jynneos in prevention of severe disease.
The news comes after the World Health Organization (WHO) declared a recent outbreak of the virus a public health emergency of international concern (PHEIC). The newest strain, clade Ib has been spreading across African countries, stemming from the Democratic Republic of Congo.
In a paper released in Cell on September 4, Moderna, best known for its mRNA Covid-19 vaccine, announced that mRNA-1769 had been more effective than the Bavarian Nordic Jynneos vaccine, one of the only two marketed mpox vaccines globally,...
Today's Sponsors
Today's Sponsor